Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with poor prognosis and high chemotherapy resistance.
• K-Ras mutations are key drivers in PDAC development and progression.
• Targeting KRas4B/PDE6δ complex stabilization is a potential therapeutic strategy for PDAC.

Purpose of the Study:

• To identify and evaluate small molecules that stabilize the KRas4B/PDE6δ complex for PDAC treatment.
• To assess the efficacy and safety of novel compounds C14 and P8 in preclinical PDAC models.

Main Methods:

• In silico screening to identify potential small molecules.
• In vitro testing of compounds C14 and P8 on primary PDAC cells and cell lines.
• In vivo studies using patient-derived xenografts and murine PDAC models.
• Analysis of downstream signaling pathways (AKT, ERK) and apoptosis induction.

Main Results:

• Compounds C14 and P8 were identified and demonstrated to reduce K-Ras activation in PDAC cells.
• C14 and P8 significantly inhibited tumor growth in patient-derived xenotransplants.
• Combined C14 and P8 treatment exhibited synergistic cytotoxicity and superior antineoplastic effects in preclinical models compared to conventional therapies, with no observed side effects.
• The mechanism involves inhibition of AKT and ERK signaling, leading to apoptosis specifically in PDAC cells.

Conclusions:

• Combined treatment with C14 and P8 represents a promising and potentially superior pharmaceutical strategy for improving outcomes in pancreatic ductal adenocarcinoma.
• These compounds offer a targeted approach by inhibiting K-RAS downstream signaling pathways, leading to specific PDAC cell death.